Skip to main content

Table 5 Adjusted models of androgen levels and 12- and 36-month outcomes stratified by the older affected sibling’s sex

From: Umbilical cord blood androgen levels and ASD-related phenotypes at 12 and 36 months in an enriched risk cohort study

Androgensa

Older affected sibling’s sex

Outcomes

  

12-month AOSI

36-month SRS

  

Beta

95% CI

P

P b

Beta

95% CI

P

P b

ln(T)

Female (n = 22)

0.91

(0.20,1.63)

0.02

0.008

0.61

(0.27,0.94)

0.001

0.006

 

Male (n = 115)

0.08

(−0.16, 0.32)

0.50

 

−0.08

(−0.30,0.14)

0.47

 

ln(A4)

Female (n = 22)

0.22

(−1.88,2.33)

0.82

0.84

1.10

(−0.07,2.28)

0.06

0.06

 

Male (n = 115)

0.05

(−0.22,0.33)

0.70

 

−0.23

(−0.48,0.02)

0.07

 

ln(DHEA)

Female (n = 22)

0.39

(−0.40,1.18)

0.32

0.36

0.18

(−0.26,0.61)

0.40

0.68

 

Male (n = 115)

0.02

(−0.20,0.24)

0.86

 

−0.06

(−0.26,0.14)

0.57

 
  1. ln natural log transformed
  2. aRobust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge (SRS raw) adjusted for infant sex, gestational age and maternal age. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale (SRS) total raw score
  3. bInteraction P value comes from a model including both subject sexes including covariates, hormone variable, subject sex, older affected sibling sex and older affected sibling sex hormone interaction